Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses the standards that illustrate quality in specialty pharmacy.

Top stories of the week on Specialty Pharmacy Times.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses changes ahead for specialty pharmacy patients.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses how health care reform has changed specialty pharmacy.

Newly discovered epigenetic markers offer hope.

Study finds most patients with Lynch syndrome are unaware they have the syndrome.

Chemotherapy drugs can convert gastrointestinal bacteria into toxic species that causes severe diarrhea.

Anticancer medication response strongly linked to genetic ancestry.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses how specialty pharmacies can best navigate complex reporting requirements from multiple entities.

Researchers seek to determine how compound from chili peppers kills prostate cancer cells.

Clinical outcomes expected to continue improving as new treatments arrive.

Top stories of the week on Specialty Pharmacy Times.

Ixazomib is the first investigational oral proteasome inhibitor for relapsed and/or refractory multiple myeloma.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.

Daratumumab monotherapy slows disease progression a year after treatment.

Experimental combination shows similar rates of HIV virologic suppression to Truvada.

Tumors linked to high blood sugar can be successfully treated without affecting blood vessel growth.

Study finds substantial minority living with undiagnosed HIV infection.

Study finds public opinion surrounding medical marijuana may influence treatment decisions.

Biologic therapy targets genetic defects found in various cancers.

Top stories of the week on Specialty Pharmacy Times.

Varubi prevents nausea and vomiting associated with vomit-inducing cancer chemotherapy.

Cancer therapy filgrastim-sndz (Zarxio) was initially approved on March 6, 2015.

Elotuzumab is an immunostimulatory antibody combination therapy for patients who received one or more prior therapies.

Afatinib treats patients with advanced squamous cell carcinoma of the lung that progressed after chemotherapy.

Paul Sipes, vice president of Spud Software, discusses how specialty pharmacies can benefit from the use of a data warehouse.

Access to high cost curative antiviral HCV drugs remains a challenge for patients.

Genetically reduced vitamin D levels could increase susceptibility to MS.

A significant increase in breast cancer development was found among a specific subset of women.